RecruitingEarly Phase 1NCT07628634

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients With Solid Tumors

Sponsor

University of California, Irvine

Enrollment

25 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

transitional cell carcinoma Soft Tissue Sarcoma Melanoma Germ Cell Tumor Lymphoma Osteosarcoma Ewing Sarcoma Leiomyosarcoma Basal Cell Carcinoma Squamous Cell Carcinoma Glioma Adenocarcinoma Rhabdomyosarcoma Endocrine Tumor Ductal Carcinoma

Summary

This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Methionine-Reduced Diet for people with adenocarcinoma, basal cell carcinoma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMethionine-Reduced Diet

Normal diet days 1-3 and 8, Methionine-Reduced Diet days 4-7, standard of care cancer treatment initiation on day 8.

Locations(1)

Chao Family Comprehensive Cancer Center, University of California, Irvine

Orange, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07628634

Related Trials

Mosaic Trial for Stem Cell Transplant Recipients

NCT069609933 locations

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT062392727 locations

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT0535570140 locations

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

NCT0461656029 locations

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

NCT0746631665 locations